Abstract
The complement system is a key regulator of the innate immune response against diseased tissue that functions across multiple organ systems. Dysregulation of complement contributes to the pathogenesis of a number of neurological diseases including stroke. The C3a anaphylatoxin, via its cognate C3a receptor (C3aR), mediates inflammation by promoting breakdown of the blood–brain barrier and the massive infiltration of leukocytes into ischemic brain in experimental stroke models. Studies utilizing complement deficient mice as well as pharmacologic C3aR antagonists have shown a reduction in tissue injury and mortality in murine stroke models. The development of tissue-specific C3aR knockout mice and more specific C3aR antagonists is warranted to facilitate our understanding of the role of the C3aR in brain ischemia with the ultimate goal of clinical translation of therapies targeting C3aR in stroke patients.
This is a preview of subscription content, log in via an institution to check access.
Reproduced with permission from Barrow Neurological Institute, Phoenix AZ
Similar content being viewed by others
References
Ames, R. S., Lee, D., Foley, J. J., Jurewicz, A. J., Tornetta, M. A., Bautsch, W., et al. (2001). Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. Journal of Immunology,166(10), 6341–6348.
Ames, R. S., Li, Y., Sarau, H. M., Nuthulaganti, P., Foley, J. J., Ellis, C., et al. (1996). Molecular cloning and characterization of the human anaphylatoxin C3a receptor. Journal of Biological Chemistry,271(34), 20231–20234.
Arumugam, T. V., Woodruff, T. M., Lathia, J. D., Selvaraj, P. K., Mattson, M. P., & Taylor, S. M. (2009). Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience,158(3), 1074–1089. https://doi.org/10.1016/j.neuroscience.2008.07.015.
Barnum, S. R., Ames, R. S., Maycox, P. R., Hadingham, S. J., Meakin, J., Harrison, D., et al. (2002). Expression of the complement C3a and C5a receptors after permanent focal ischemia: An alternative interpretation. Glia,38(2), 169–173.
Beatty, W. K., & Beatty, V. L. (1975). Medical school libraries in the United States and Canada built between 1961 and 1971. Bulletin of the Medical Library Association,63(3), 324–336.
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., et al. (2017). Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation,135(10), e146–e603. https://doi.org/10.1161/cir.0000000000000485.
Blatt, A. Z., Pathan, S., & Ferreira, V. P. (2016). Properdin: A tightly regulated critical inflammatory modulator. Immunological Reviews,274(1), 172–190. https://doi.org/10.1111/imr.12466.
Bogestal, Y. R., Barnum, S. R., Smith, P. L., Mattisson, V., Pekny, M., & Pekna, M. (2007). Signaling through C5aR is not involved in basal neurogenesis. Journal of Neuroscience Research,85(13), 2892–2897. https://doi.org/10.1002/jnr.21401.
Boos, L., Szalai, A. J., & Barnum, S. R. (2005). C3a expressed in the central nervous system protects against LPS-induced shock. Neuroscience Letters,387(2), 68–71. https://doi.org/10.1016/j.neulet.2005.07.015.
Caporale, L. H., Tippett, P. S., Erickson, B. W., & Hugli, T. E. (1980). The active site of C3a anaphylatoxin. Journal of Biological Chemistry,255(22), 10758–10763.
Carpanini, S. M., Torvell, M., & Morgan, B. P. (2019). Therapeutic inhibition of the complement system in diseases of the central nervous system. Frontiers in Immunology,10, 362. https://doi.org/10.3389/fimmu.2019.00362.
Chao, T. H., Ember, J. A., Wang, M., Bayon, Y., Hugli, T. E., & Ye, R. D. (1999). Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function. Journal of Biological Chemistry,274(14), 9721–9728.
Chen, Y., Tsai, Y. H., & Tseng, S. H. (2011). The potential of tetrandrine as a protective agent for ischemic stroke. Molecules,16(9), 8020–8032. https://doi.org/10.3390/molecules16098020.
Crass, T., Ames, R. S., Sarau, H. M., Tornetta, M. A., Foley, J. J., Kohl, J., et al. (1999). Chimeric receptors of the human C3a receptor and C5a receptor (CD88). Journal of Biological Chemistry,274(13), 8367–8370.
Dando, S. J., Mackay-Sim, A., Norton, R., Currie, B. J., St John, J. A., Ekberg, J. A., et al. (2014). Pathogens penetrating the central nervous system: Infection pathways and the cellular and molecular mechanisms of invasion. Clinical Microbiology Reviews,27(4), 691–726. https://doi.org/10.1128/CMR.00118-13.
Daneman, R., & Prat, A. (2015). The blood-brain barrier. Cold Spring Harbor Perspectives in Biology,7(1), a020412. https://doi.org/10.1101/cshperspect.a020412.
Davoust, N., Jones, J., Stahel, P. F., Ames, R. S., & Barnum, S. R. (1999). Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia,26(3), 201–211.
de Vries, B., Walter, S. J., Peutz-Kootstra, C. J., Wolfs, T. G., van Heurn, L. W., & Buurman, W. A. (2004). The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. American Journal of Pathology,165(5), 1677–1688. https://doi.org/10.1016/S0002-9440(10)63424-4.
Ducruet, A. F., Hassid, B. G., Mack, W. J., Sosunov, S. A., Otten, M. L., Fusco, D. J., et al. (2008). C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. Journal of Cerebral Blood Flow and Metabolism,28(5), 1048–1058. https://doi.org/10.1038/sj.jcbfm.9600608.
Ducruet, A. F., Zacharia, B. E., Hickman, Z. L., Grobelny, B. T., Yeh, M. L., Sosunov, S. A., et al. (2009). The complement cascade as a therapeutic target in intracerebral hemorrhage. Experimental Neurology,219(2), 398–403. https://doi.org/10.1016/j.expneurol.2009.07.018.
Ducruet, A. F., Zacharia, B. E., Sosunov, S. A., Gigante, P. R., Yeh, M. L., Gorski, J. W., et al. (2012). Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. PLoS ONE,7(6), e38664. https://doi.org/10.1371/journal.pone.0038664.
Ehlers, M. R. (2000). CR22: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes and Infection,2(3), 289–294.
Gravanis, I., & Tsirka, S. E. (2008). Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opinion on Therapeutic Targets,12(2), 159–170. https://doi.org/10.1517/14728222.12.2.159.
Heurich, B., El Idrissi, N. B., Donev, R. M., Petri, S., Claus, P., Neal, J., et al. (2011). Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Journal of Neuroimmunology,235(1–2), 104–109. https://doi.org/10.1016/j.jneuroim.2011.03.011.
Jacob, A., & Alexander, J. J. (2014). Complement and blood-brain barrier integrity. Molecular Immunology,61(2), 149–152. https://doi.org/10.1016/j.molimm.2014.06.039.
Jarlestedt, K., Rousset, C. I., Stahlberg, A., Sourkova, H., Atkins, A. L., Thornton, C., et al. (2013). Receptor for complement peptide C3a: A therapeutic target for neonatal hypoxic-ischemic brain injury. The FASEB Journal,27(9), 3797–3804. https://doi.org/10.1096/fj.13-230011.
Jauneau, A. C., Ischenko, A., Chatagner, A., Benard, M., Chan, P., Schouft, M. T., et al. (2006). Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. Journal of Neuroinflammation,3, 8. https://doi.org/10.1186/1742-2094-3-8.
Jin, K., Minami, M., Lan, J. Q., Mao, X. O., Batteur, S., Simon, R. P., et al. (2001). Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proceedings of the National Academy of Sciences of the United States of America,98(8), 4710–4715. https://doi.org/10.1073/pnas.081011098.
Kalogeris, T., Baines, C. P., Krenz, M., & Korthuis, R. J. (2012). Cell biology of ischemia/reperfusion injury. International Review of Cell and Molecular Biology,298, 229–317. https://doi.org/10.1016/B978-0-12-394309-5.00006-7.
Lacy, M., Jones, J., Whittemore, S. R., Haviland, D. L., Wetsel, R. A., & Barnum, S. R. (1995). Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. Journal of Neuroimmunology,61(1), 71–78.
Leblhuber, F., Walli, J., Jellinger, K., Tilz, G. P., Widner, B., Laccone, F., et al. (1998). Activated immune system in patients with Huntington’s disease. Clinical Chemistry and Laboratory Medicine,36(10), 747–750. https://doi.org/10.1515/CCLM.1998.132.
Liu, S., Feng, X., Jin, R., & Li, G. (2018). Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. Expert Opinion on Drug Delivery,15(2), 173–184. https://doi.org/10.1080/17425247.2018.1384464.
Lohman, R. J., Hamidon, J. K., Reid, R. C., Rowley, J. A., Yau, M. K., Halili, M. A., et al. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications,8(1), 351. https://doi.org/10.1038/s41467-017-00414-w.
Martin, U., Bock, D., Arseniev, L., Tornetta, M. A., Ames, R. S., Bautsch, W., et al. (1997). The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. Journal of Experimental Medicine,186(2), 199–207.
Mathieu, M. C., Sawyer, N., Greig, G. M., Hamel, M., Kargman, S., Ducharme, Y., et al. (2005). The C3a receptor antagonist SB 290157 has agonist activity. Immunology Letters,100(2), 139–145. https://doi.org/10.1016/j.imlet.2005.03.003.
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). Complement system part I—Molecular mechanisms of activation and regulation. Frontiers in Immunology,6, 262. https://doi.org/10.3389/fimmu.2015.00262.
Miller, D. J., Simpson, J. R., & Silver, B. (2011). Safety of thrombolysis in acute ischemic stroke: A review of complications, risk factors, and newer technologies. Neurohospitalist,1(3), 138–147. https://doi.org/10.1177/1941875211408731.
Mocco, J., Wilson, D. A., Komotar, R. J., Sughrue, M. E., Coates, K., Sacco, R. L., et al. (2006). Alterations in plasma complement levels after human ischemic stroke. Neurosurgery,59(1), 28–33. https://doi.org/10.1227/01.neu.0000219221.14280.65. (discussion 28–33).
Mollnes, T. E., Song, W. C., & Lambris, J. D. (2002). Complement in inflammatory tissue damage and disease. Trends in Immunology,23(2), 61–64.
Morgan, B. P. (2018). Complement in the pathogenesis of Alzheimer’s disease. Seminars in Immunopathology,40(1), 113–124. https://doi.org/10.1007/s00281-017-0662-9.
Norgauer, J., Dobos, G., Kownatzki, E., Dahinden, C., Burger, R., Kupper, R., et al. (1993). Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. European Journal of Biochemistry,217(1), 289–294.
Noris, M., & Remuzzi, G. (2013). Overview of complement activation and regulation. Seminars in Nephrology,33(6), 479–492. https://doi.org/10.1016/j.semnephrol.2013.08.001.
O’Barr, S. A., Caguioa, J., Gruol, D., Perkins, G., Ember, J. A., Hugli, T., et al. (2001). Neuronal expression of a functional receptor for the C5a complement activation fragment. Journal of Immunology,166(6), 4154–4162.
Pfisterer, U., & Khodosevich, K. (2017). Neuronal survival in the brain: Neuron type-specific mechanisms. Cell Death & Disease,8(3), e2643. https://doi.org/10.1038/cddis.2017.64.
Rahpeymai, Y., Hietala, M. A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A. K., et al. (2006). Complement: A novel factor in basal and ischemia-induced neurogenesis. EMBO Journal,25(6), 1364–1374. https://doi.org/10.1038/sj.emboj.7601004.
Reemst, K., Noctor, S. C., Lucassen, P. J., & Hol, E. M. (2016). The indispensable roles of microglia and astrocytes during brain development. Frontiers in Human Neuroscience,10, 566. https://doi.org/10.3389/fnhum.2016.00566.
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010). Complement: A key system for immune surveillance and homeostasis. Nature Immunology,11(9), 785–797. https://doi.org/10.1038/ni.1923.
Schafer, M. K., Schwaeble, W. J., Post, C., Salvati, P., Calabresi, M., Sim, R. B., et al. (2000). Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. Journal of Immunology,164(10), 5446–5452.
Settmacher, B., Rheinheimer, C., Hamacher, H., Ames, R. S., Wise, A., Jenkinson, L., et al. (2003). Structure-function studies of the C3a-receptor: C-terminal serine and threonine residues which influence receptor internalization and signaling. European Journal of Immunology,33(4), 920–927. https://doi.org/10.1002/eji.200323293.
Shen, Y., Li, R., McGeer, E. G., & McGeer, P. L. (1997). Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Research,769(2), 391–395.
Shinjyo, N., Stahlberg, A., Dragunow, M., Pekny, M., & Pekna, M. (2009). Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells,27(11), 2824–2832. https://doi.org/10.1002/stem.225.
Sochocka, M., Diniz, B. S., & Leszek, J. (2017). Inflammatory response in the CNS: Friend or foe? Molecular Neurobiology,54(10), 8071–8089. https://doi.org/10.1007/s12035-016-0297-1.
Stokowska, A., Atkins, A. L., Moran, J., Pekny, T., Bulmer, L., Pascoe, M. C., et al. (2017). Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia. Brain,140(2), 353–369. https://doi.org/10.1093/brain/aww314.
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., et al. (2003). VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. Journal of Clinical Investigation,111(12), 1843–1851. https://doi.org/10.1172/JCI17977.
Therien, A. G. (2005). Agonist activity of the small molecule C3aR ligand SB 290157. Journal of Immunology,174(12), 7479. (author reply 7479–7480).
Thomas, A., Gasque, P., Vaudry, D., Gonzalez, B., & Fontaine, M. (2000). Expression of a complete and functional complement system by human neuronal cells in vitro. International Immunology,12(7), 1015–1023.
Thurman, J. M., & Holers, V. M. (2006). The central role of the alternative complement pathway in human disease. Journal of Immunology,176(3), 1305–1310.
Tornetta, M. A., Foley, J. J., Sarau, H. M., & Ames, R. S. (1997). The mouse anaphylatoxin C3a receptor: Molecular cloning, genomic organization, and functional expression. Journal of Immunology,158(11), 5277–5282.
Van Beek, J., Bernaudin, M., Petit, E., Gasque, P., Nouvelot, A., MacKenzie, E. T., et al. (2000). Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Experimental Neurology,161(1), 373–382. https://doi.org/10.1006/exnr.1999.7273.
Vasek, M. J., Garber, C., Dorsey, D., Durrant, D. M., Bollman, B., Soung, A., et al. (2016). A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature,534(7608), 538–543. https://doi.org/10.1038/nature18283.
Veerhuis, R., Janssen, I., De Groot, C. J., Van Muiswinkel, F. L., Hack, C. E., & Eikelenboom, P. (1999). Cytokines associated with amyloid plaques in Alzheimer’s disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Experimental Neurology,160(1), 289–299. https://doi.org/10.1006/exnr.1999.7199.
Veerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011). Complement in the brain. Molecular Immunology,48(14), 1592–1603. https://doi.org/10.1016/j.molimm.2011.04.003.
Walker, D. G., Kim, S. U., & McGeer, P. L. (1998). Expression of complement C4 and C9 genes by human astrocytes. Brain Res, 809(1), 31–38.
Wang, Y., Hancock, A. M., Bradner, J., Chung, K. A., Quinn, J. F., Peskind, E. R., et al. (2011). Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. American Journal of Pathology,178(4), 1509–1516. https://doi.org/10.1016/j.ajpath.2011.01.006.
Woodruff, T. M., Ager, R. R., Tenner, A. J., Noakes, P. G., & Taylor, S. M. (2010). The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Medicine,12(2), 179–192. https://doi.org/10.1007/s12017-009-8085-y.
Woodruff, T. M., Thundyil, J., Tang, S. C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011). Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Molecular Neurodegeneration,6(1), 11. https://doi.org/10.1186/1750-1326-6-11.
Xiong, C., Liu, J., Lin, D., Zhang, J., Terrando, N., & Wu, A. (2018). Complement activation contributes to perioperative neurocognitive disorders in mice. Journal of Neuroinflammation,15(1), 254. https://doi.org/10.1186/s12974-018-1292-4.
Yanamadala, V., & Friedlander, R. M. (2010). Complement in neuroprotection and neurodegeneration. Trends in Molecular Medicine,16(2), 69–76. https://doi.org/10.1016/j.molmed.2009.12.001.
Zhao, X. J., Larkin, T. M., Lauver, M. A., Ahmad, S., & Ducruet, A. F. (2017). Tissue plasminogen activator mediates deleterious complement cascade activation in stroke. PLoS ONE,12(7), e0180822. https://doi.org/10.1371/journal.pone.0180822.
Acknowledgements
Research in the authors’s lab is funded by the Barrow Neurological Foundation. The authors thank the staff of Neuroscience Publications at Barrow Neurological Institute for assistance with figure preparation. We thank to Ms. Tasha Mohseni for her editorial assistance with manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ahmad, S., Bhatia, K., Kindelin, A. et al. The Role of Complement C3a Receptor in Stroke. Neuromol Med 21, 467–473 (2019). https://doi.org/10.1007/s12017-019-08545-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-019-08545-7